Research on colorectal and bowel cancer. Covers AI-audited colonoscopy, gut-bacteria links, family risk, and early-onset differences.
The American Cancer Society report reveals progress in reducing cancer death rates among African-Americans, but racial disparities persist in breast and colorectal cancers. The study finds that disparities in access to care and screening contribute to these disparities.
A new Canadian guideline recommends fecal occult blood testing (FOBT) every two years or flexible sigmoidoscopy every 10 years for routine screening of colorectal cancer in asymptomatic, low-risk adults aged 50-74. The guideline also recommends against colonoscopy as a primary screening tool, citing lack of direct evidence.
Colorectal cancer patients require follow-up colonoscopy after surgery to detect second cancers and polyps, with recommended intervals varying from one to nine years. The US Multi-Society Task Force updates guidelines to emphasize the role of colonoscopy in post-surgical surveillance.
A study of US data found that one in seven colorectal cancer patients is younger than 50 years old, often presenting with advanced stage disease. However, these patients tend to receive more aggressive therapy and have a slightly longer survival rate without recurrence.
Research by Michigan Medicine found that nearly 15% of colorectal cancer patients were diagnosed before age 50, often with more advanced disease. Younger patients had better survival rates due to aggressive treatment, suggesting the need for improved long-term survivorship resources.
The American College of Physicians (ACP) offers guidance on evaluating blood in the urine, emphasizing the importance of referring patients with gross hematuria and confirming heme-positive results. For adults with microscopically confirmed hematuria, urology referral for cystoscopy and imaging is recommended.
A University of Colorado study found distinct genetic drivers in colorectal cancer among young and old patients, with potential implications for targeted therapies.
Research at Thomas Jefferson University reveals obesity is associated with a key hormone's absence, leading to tumor suppressor pathway deactivation and increased colorectal cancer risk. A therapeutic approach using the pill linaclotide, structurally related to the lost hormone, may prevent cancer in obese patients.
Seven scientists with novel approaches to fighting cancer have been named recipients of the Damon Runyon-Rachleff Innovation Award. The grant funds cancer research by exceptionally creative thinkers with 'high-risk/high-reward' ideas, aiming to significantly impact cancer prevention, diagnosis, and treatment.
A recent US study found that minority and ethnic groups are being diagnosed with colorectal cancer at younger ages than non-Hispanic whites. The study reveals that these groups have twice the risk of developing the disease before age 50, with advanced stages at diagnosis.
Researchers at University of Missouri-Columbia discovered that the gene Sprouty2, previously believed to suppress cancer growth, may actually promote metastasis in colorectal cancer. This finding has significant implications for understanding and treating the disease.
A new study by Sylvester researchers describes the immune system's response to tumor development, highlighting the stimulator of interferon genes (STING) signaling pathway's potential suppression of colorectal cancer. Impaired STING responses may enable damaged cells to evade the immune system.
A study published in JNCI Journal of the National Cancer Institute found that virtual colonoscopy had higher detection rates than traditional methods like FIT and OC. The researchers concluded that combination of lower attendance and higher detection rate makes CTC a key factor for optimization of its role in population screening.
A new American Cancer Society study reveals that excess medical expenditures and productivity losses vary significantly among cancer survivors by age and cancer site. Nonelderly survivors of colorectal and breast cancers experience higher annual expenditures compared to those without a cancer history.
A study published in JAMA found that nearly half of working individuals with stage III colorectal cancer lost their jobs due to their diagnosis. However, those with access to paid sick leave were more likely to retain their jobs and experience reduced personal financial burdens. The study highlights the importance of providing paid sic...
A new study reveals that Latinos from Mexico have the lowest chance of getting colorectal cancer, while those from Central or South America are diagnosed with the disease before age 50 at a higher rate. The research aims to pave the way for personalized cancer care and reduce disparities in treatment
Scientists have mapped out the human genome to identify essential genes for cell survival, revealing a core set of over 1,500 genes. The findings suggest that each tumor relies on a unique set of genes that can be targeted by specific drugs, offering hope for devising new treatments.
A city-wide initiative in NYC increased colorectal cancer screening colonoscopy rates from 42% to 62% and eliminated disparities based on race/ethnicity. The program included public education, outreach to healthcare providers, and culturally tailored campaigns to boost awareness and overcome hurdles to effective screening.
A city-wide coalition launched by NYC DOHMH and Mount Sinai resulted in a 40% increase in colorectal cancer screening rates over four years. Screening rates rose from 42% in 2003 to 62% in 2007, with significant reductions in disparities based on ethnicity.
A study at MD Anderson Cancer Center reveals that increased methylation of epidermal growth factor receptors (EGFR) leads to resistance to cetuximab antibody therapy, resulting in poorer clinical outcomes and higher recurrence rates. The study also found that expression of methylation-defective EGFR reduces tumor growth in mice.
A study by CDC found that poorer communities bear the greatest economic burden due to colorectal cancer deaths. The researchers estimated $4.2 billion in productivity gains if eliminateable deaths are avoided.
A new stool DNA test has been found accurate in screening for colorectal cancer among Alaska Native people, a population with one of the world's highest rates of the disease. The test detected significantly more screen-relevant neoplasms than traditional fecal occult blood testing methods.
Researchers have identified a small RNA molecule, SNORA42, that enables aggressive colorectal cancers to progress and resist treatment. Detecting high levels of this biomarker in patient tissues may help clinicians determine which patients benefit from more aggressive therapy.
Researchers found no significant difference in new polyp formation between patients with vitamin D and/or calcium supplements and those without. The study's results contradict previous findings in models and smaller human trials, highlighting the need for further research on promising cancer prevention strategies.
A University of Colorado Cancer Center study found TAK-733 to be highly active against colorectal cancer cells and tumors, with 42 of 54 cell lines sensitive to the drug. However, inconsistent absorption and bioavailability were observed, raising concerns about safety and tolerability.
A study by the University of Melbourne found a significant disparity in bowel cancer deaths between European men and women. Lifestyle factors such as diet, smoking, and alcohol consumption are linked to higher rates of bowel cancer in men. The researchers suggest that countries with high levels of screening have seen substantial reduct...
A study published in The BMJ reveals significant disparities in bowel cancer mortality rates across Europe, with notable variations between men and women and different regions. Colorectal cancer mortality has decreased in many European countries over the past two decades, but important differences remain.
A study published in Clinical Gastroenterology and Hepatology suggests that all relatives of individuals with colorectal cancer are at increased risk for this cancer, regardless of their age. The risk is highest among young first-degree relatives under 50 years old.
A researcher is calling for updated guidelines on colorectal cancer screening, citing evidence that most patients with a family history of the disease can stop aggressive screening at age 65. The study found that the risk of colorectal cancer diagnosis decreases with increasing age in patients with a family history.
A study based on over 10 million patients found that family health teams led to improved diabetes monitoring and screening rates. Patients in these teams were more likely to receive recommended testing and screenings for breast cancer and colorectal cancer.
Researchers at Nanjing University have discovered new epigenetic markers for colorectal cancer, which may offer a new approach for treatment. The study found that heterochromatin protein HP1γ was critical for CRC cell proliferation and could be specially regulated by miR-30a.
The American Gastroenterological Association recommends testing all newly diagnosed cases of colorectal cancer to identify Lynch syndrome, a genetic disorder that increases the risk of colorectal and endometrial cancers. Regular surveillance colonoscopy is also recommended for individuals with Lynch syndrome.
Researchers have developed a new risk assessment scoring system to stratify risk for advanced neoplasia in asymptomatic adults. The study found that patients with lower risk scores may be suitable for less invasive tests such as sigmoidoscopies or occult blood tests.
A study found that examining the right side of the colon while patients lie on their left side increases polyp and adenoma detection. This position change also improved distension of the colon, allowing for better visualization. The results suggest a more effective tool for ongoing surveillance and prevention.
Researchers analyzed data from patients undergoing stage IV colorectal cancer surgery to identify benchmarks for surgical practice. They found that major complications vary depending on the extent of liver resection and type of colorectal surgery performed.
A research team has discovered a mechanism to mimic a viral infection in colon cancer stem cells, which could potentially trigger an immune response to fight the disease. Decitabine, a chemotherapy drug, is identified as a potential target to induce viral mimicry and activate an anti-viral response.
A new testing method developed to accurately detect PMS2 gene mutations has been shown to improve diagnosis and support genetic counseling and medical management for individuals with Lynch syndrome. The approach combines targeted capture next-generation sequencing, multiplex ligation-dependent probe amplification, and long-range PCR fo...
A population-based case-control study found that long-term, continuous use of low-dose aspirin and nonaspirin nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with decreased colorectal cancer risk. The study also suggests that higher COX-2 selectivity in nonaspirin NSAIDs may offer greater protection.
The European Society for Medical Oncology (ESMO) announced the award of its esteemed prizes to three exceptional medical oncologists: Nathan Cherny, Nagahiro Saijo, and Cornelis Punt. These pioneers have made groundbreaking contributions to palliative care integration, medical oncology in Asia, and immunotherapy approaches.
Researchers at Arizona State University have identified a link between chronic inflammation and colon cancer metastasis. The study found that prostaglandin E2 (PGE2) triggers the spread of cancer cells to other organs, leading to increased tumor burden and chemotherapy resistance.
Researchers at VIB and KU Leuven found that inhibiting PHD1 prevents p53 activation, leading to improved response to chemotherapy in colorectal cancer cells. This discovery offers new therapeutic potential for increasing sensitivity to chemotherapeutic treatments.
A study at the University of Texas MD Anderson Cancer Center found that CSN6 is overexpressed in colorectal cancer tissue samples, leading to poor survival rates. The biomarker's deregulation can lead to cancer development through cellular signaling pathways.
A new study reveals that Louisiana's colorectal cancer incidence and mortality rates would drop significantly if the state had the same risk factors, screening rates, and survival rates as New Jersey. With these changes, Louisiana's rates would be lower than those in New Jersey, essentially reversing recent trends.
A new study by Georgia State University researchers found that state regulations significantly influence when patients receive cancer diagnoses, particularly among people under 65. The study suggests that where people live is a strong predictor of whether they will receive potentially life-saving cancer screenings.
Researchers found that 35% of patients with early-onset colorectal cancer (diagnosed before age 35) have a genetic disease, highlighting the need for genetic counseling to identify high-risk family members. Gene panel testing is recommended to uncover underlying mutations, allowing for preventive measures and earlier screening.
A large trial shows liquid biopsy (BEAMing technology) detects tumor genotypes not found in tissue biopsies, enabling targeted therapy selection. Regorafenib benefits patients with KRAS and PIK3CA mutations, revolutionizing colorectal cancer treatment.
Patients whose colorectal cancer is detected during a screening colonoscopy tend to live longer than those who wait until symptoms appear. The study found that these patients had cancer at an earlier stage and were more likely to survive beyond the study period, with about 55% surviving beyond the time of diagnosis.
A new study found that young adult cancer survivors are hospitalized 1.5 times as often as people in a control group, with higher rates for gastrointestinal and urological cancers. The study highlights the ongoing impact of cancer on young adults' lives and long-term health.
Patients with metastatic colorectal cancer (mCRC) and quadruple wild-type genes showed significant benefit from continuing anti-EGFR therapy beyond progression. Second-line cetuximab plus FOLFOX chemotherapy improved progression-free survival, response rate, and overall survival in patients without genetic mutations.
A phase IIIb study has confirmed regorafenib's benefit in patients with previously treated metastatic colorectal cancer. The safety profile and progression-free survival were similar to phase III trial results, with a median duration of 2.5 months.
A pooled analysis of patients with metastatic colorectal cancer (mCRC) treated with bevacizumab found that those with the lowest body mass index (BMI) had significantly shorter overall survival compared to other BMI categories. Progression-free survival was similar across all subgroups.
The SENRI trial found that NK1 antagonists significantly increased the inhibition rate of vomiting and nausea, especially in females. The three-drug combination therapy of aprepitant, a 5-HT3 receptor antagonist, and dexamethasone may be a good antiemetic treatment option for oxaliplatin-based chemotherapy in patients with colorectal c...
Patients with a low to healthy body weight had an average survival time of two-and-a-half months less than overweight and obese patients. The study suggests that there may be a relationship between having a lower BMI and poor treatment tolerance, putting thinner patients at risk for poor outcomes.
A recent study discovered that Daple protein is a tumor suppressor in the early stages of colorectal cancer, but may actually facilitate disease spread at later stages. Researchers found that higher levels of Daple were associated with better patient survival rates and lower tumor growth.
Researchers have discovered a gene called SMOC-2 that plays a crucial role in the spread of colorectal cancer. Increased levels of SMOC-2 enable tumor cells to 'leave home' and metastasize, while blocking its activation inhibits metastasis. The gene's expression patterns also resemble those of healthy intestinal stem cells.
Researchers developed an electrochemical platform to measure DNMT1 activity, a protein linked to cancerous transformation, in crude tissue samples. The technique shows promise for early detection of colorectal cancer with high sensitivity and minimal invasion.
Researchers at St. Jude Children's Research Hospital have found a way to prevent or slow progression of colorectal cancer by boosting the activity of a protective gene called AIM2 and giving patients healthy donor bacteria.
Researchers found that reactivating a single gene turned colorectal cancer cells back into normal tissue within days, stopping tumor growth and eliminating signs of cancer. The study provides proof of principle for developing effective cancer treatments by targeting specific tumor suppressor genes.
Researchers identified two genes, ERCC1 and TS, that can predict positive response to chemotherapy and longer survival times in metastatic colorectal cancer patients. Low levels of these genes are associated with improved survival rates when treated with oxaliplatin, while high levels may require irinotecan as the first treatment choice.
A study of over 57,000 screenings found that higher adenoma detection rates are associated with a 53-60% lower lifetime risk of colorectal cancer and death. However, the cost-effectiveness remains uncertain despite potential complications from more frequent colonoscopies.